Karyopharm reports third quarter 2024 financial results and highlights recent company progress

– achieves third quarter 2024 total revenue of $38.8 million and u.s. xpovio® (selinexor) net product revenue of $29.5 million; continued regulatory and reimbursement approvals globally – – following fda alignment, absolute change in total symptom score (abs-tss) will replace tss50 as a co-primary endpoint in phase 3 sentry trial in jaki naÏve myelofibrosis (mf); expected top-line data read-out remains on track for 2h 2025 – – narrows full-year 2024 total revenue guidance range to $145.0 million to $155.0 million; u.s. xpovio net product revenue guidance range to $110.0 million to $115.0 million; r&d and sg&a expense guidance range to $255.0 million to $265.0 million – newton, mass. , nov. 5, 2024 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended september 30, 2024, and highlighted select corporate milestones and progress on its key clinical development programs.
KPTI Ratings Summary
KPTI Quant Ranking